Company intelligence / Profile preview

Spliceor

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Spliceor is developing a patented cancer-selective trans‑splicing gene therapy platform with preclinical programs initially focused on liver and pancreatic cancers; no human clinical trial results have been reported yet.

Therapeutic areas: Oncology
Modalities: Gene therapy
Industry: Biotech

Partnerships

Cell and Gene Therapy Catapult (investment and collaboration around the trans‑splicing gene therapy platform)Start Codon (seed accelerator/investor)Amadeus Capital Partners (investor/partner)

Beyond the preview

Go deeper on Spliceor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spliceor.

Explore the full profile